TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01966666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 2 mg/m2
Description: 2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 6.3 mg/m2
Description: 6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 20 mg/m2
Description: 20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500mL 0.9% sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500mL 0.9% sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500mL 0.9% sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500mL 0.9% sodium chloride.
Study: NCT01815736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/FTC/TDF
Description: 600/200/300 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: 100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: 300 mg capsule administered orally once daily
Study: NCT00473863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomographic Angiography
Description: CCTA will be performed
Study: NCT04259476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: low dose perioperative ketamine infusion. and its effects on post-operative pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: low dose perioperative ketamine infusion. and its effects on post-operative pain.
Study: NCT01098591

Intervention type: OTHER
Intervention: cell therapy
Study: NCT00195351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tigecycline
Description: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone sodium + metronidazole
Description: Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
Study: NCT02134379

Intervention type: DEVICE
Intervention: Medtronic ICDs, CRT-Ds, and CRT-Ps
Description: Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
Study: NCT01470976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal-directed Resuscitation Therapy (GDT)
Description: * A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~* The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~* When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
Study: NCT02634515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Julphar Insulin R (soluble human insulin, biosimilar)
Description: investigational insulin, Julphar Insulin R (soluble human insulin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huminsulin® Normal (soluble human insulin, reference)
Description: marketed product, Huminsulin® Normal (soluble human insulin
Study: NCT02614846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Study: NCT03914352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
Study: NCT01392690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dominique's Handy Tricks
Description: Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
Study: NCT03038724

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid HIV test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid HIV test
Study: NCT02818010

Intervention type: OTHER
Intervention: Global Physical Activity Questionnaire
Description: The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.

Intervention type: OTHER
Intervention: Global Physical Activity Questionnaire
Description: The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
Study: NCT02054832

Intervention type: DIETARY_SUPPLEMENT
Intervention: Glycosade
Study: NCT03797443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: 30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
Study: NCT03058614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEUS
Description: In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Non-contrast CT scan
Description: The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capping trial
Description: Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
Study: NCT04216329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
Study: NCT01815736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally once daily
Study: NCT03422601

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoscore test
Description: To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoscore test
Description: To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
Study: NCT01598571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose
Study: NCT04095195

Intervention type: RADIATION
Intervention: MRCP
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: RADIATION
Intervention: MRCP
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: RADIATION
Intervention: MRCP
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: RADIATION
Intervention: MRCP
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: RADIATION
Intervention: MRCP
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: RADIATION
Intervention: MRCP
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: PROCEDURE
Intervention: Endoultrasonography
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: PROCEDURE
Intervention: Endoultrasonography
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: PROCEDURE
Intervention: Endoultrasonography
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: PROCEDURE
Intervention: Endoultrasonography
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: PROCEDURE
Intervention: Endoultrasonography
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription

Intervention type: PROCEDURE
Intervention: Endoultrasonography
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription
Study: NCT04438733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test-anastrozole tablet (Salutas Pharma GmbH)
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference-anastrozole tablet (Arimidex)
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
Study: NCT04410146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID Embolization
Description: Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID Embolization and Surgical Evacuation
Description: Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent and the surgical evacuation of the sub-dural hematoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Evacuation
Description: Surgical evacuation of the sub-dural hematoma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Medical Management
Description: Standard
Study: NCT01815736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI
Description: 150 mg tablet administered orally once daily
Study: NCT02392884

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
Study: NCT00874809

Intervention type: DEVICE
Group type: OTHER
Intervention: CGMS with an insulin pump using rapid acting insulin
Description: To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
Study: NCT00412451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection, single administration

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham intravitreal injection
Study: NCT05202496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25Mcg Cap
Description: After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
Study: NCT03797443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study: NCT03240081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50mcg estradiol cream
Description: Use of study drug nightly applied to vulvar vestibule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mcg estradiol cream
Description: Use of study drug nightly
Study: NCT00648310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
Study: NCT01843322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoleak repair procedure (navigation technology )
Study: NCT00772395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Study: NCT04216329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m\^2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-radiation therapy (RT), the adjuvant temozolomide will be given per standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Generic Radiation therapy (RT)
Description: Radiation therapy (RT) will be administered daily (Monday to Friday)
Study: NCT05202496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Description: experimental group subjects undergo orthodontic treatment after extraction of premolars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment
Description: experimental group subjects undergo orthodontic treatment after extraction of premolars
Study: NCT04216329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective serotonin receptor (5-HT3) antagonists
Description: Anti-emetic for breakthrough nausea.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5mg to 5mg once a day if weight loss is rapid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt tablets
Description: To treat hyponatremia, add salt tablets to participants diet per institutional guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-diarrheal
Description: Treat diarrhea with an anti-diarrheal per institutional guidelines
Study: NCT00806117

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (RT)
Description: External irradiation 50Gy/5 weeks~* Lateral: 2 cm lateral to the bony margin of the pelvis~* Superior: Between L5 and S1~* Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)
Study: NCT00835666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg tablets
Description: 1 x 5 mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROSCAR®
Description: 1 x 5 mg, single dose fasting
Study: NCT00806117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation (CCRT)
Description: Cisplatin 40mg/m2 every week during external irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence chemotherapy and radiotherapy (SCRT)
Description: Paclitaxel 135\~175mg/m2 over 3 hours Cisplatin 60\~75mg/m2
Study: NCT03656393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib (250 mg, orally, every day) for 56 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
Study: NCT05751525

Intervention type: DRUG
Intervention: Sulfonylurea
Description: Glibenlclamide / glyburide

Intervention type: DRUG
Intervention: Sulfonylurea
Description: Glibenlclamide / glyburide
Study: NCT03656393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
Study: NCT01281553

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension identical in appearance to cisapride q.i.d. for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisapride
Description: 0.2 mg/kg suspension q.i.d.for 8 weeks.
Study: NCT03893487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimepinostat
Description: Fimepinostat capsules

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04450069

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CLBR001 and SWI019
Description: Investigational immunotherapy for B cell malignancies
Study: NCT00859521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 1000 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra®
Description: 1000 mg Tablet
Study: NCT02855853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serious game et virtual reality

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nintendo Wii
Study: NCT02724605

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Red blood cells unit age 14 days or less
Description: 30 Patients who will receive units of packed red blood cells stored stored for 14 days or less

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Red blood cells unit age more than 14 days
Description: 30 patients who will receive units of packed red blood cells stored for more than 14 days
Study: NCT01693523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth two times a day (200 mg/day).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules by mouth twice a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
Study: NCT01020331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study: NCT01693523

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
Study: NCT04538677

Intervention type: DEVICE
Intervention: Video consultation
Description: A two-way audio and visual connection between patients and surgeons
Study: NCT01368991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kryptonite
Description: Osteoconductive biologic bone cement to be applied upon sternal closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional closure
Description: conventional closure, no kryptonite applied
Study: NCT00849823

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Male Sexual Health Program
Description: An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus on the Future Program
Description: A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.